Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
INFUVITE ADULT (multiple vitamins injection) is a sterile product consisting of two vials provided as a single dose or as a pharmacy bulk package, both intended for intravenous use for administration by intravenous infusion after dilution:
INFUVITE ADULT Single Dose -two 5 mL single-dose vials labeled Vial 1 and Vial 2.
INFUVITE ADULT Pharmacy Bulk Package -two vials – 1 each of Vial 1 (50 mL) and Vial 2 (50 mL Fill in 100 mL Vial). The mixed solution (100 mL) will provide ten 10 mL single doses.
Each 5 mL of Vial 1 contains:
| Ascorbic acid (Vitamin C) | 200 mg |
| Vitamin A* (as palmitate) | 3,300 IU |
| Vitamin D3* (cholecalciferol) | 200 IU |
| Thiamine (Vitamin B1) (as the hydrochloride) | 6 mg |
| Riboflavin (Vitamin B2) | |
| (as riboflavin 5-phosphate sodium) | 3.6 mg |
| Pyridoxine HCl (Vitamin B6) | 6 mg |
| Niacinamide | 40 mg |
| Dexpanthenol | |
| (as d-pantothenyl alcohol) | 15 mg |
| Vitamin E* (dl-α-tocopheryl acetate) | 10 IU |
| Vitamin K1* | 150 mcg |
Inactive ingredients: 1.4% polysorbate 80, sodium hydroxide and/or hydrochloric acid for pH adjustment, and water for injection.
*Polysorbate 80 is used to water solubilize the oil-soluble vitamins A, D, E, and K.
Each 5 mL of Vial 2 contains:
| Folic acid | 600 mcg |
| Biotin | 60 mcg |
| Vitamin B12 (cyanocobalamin) | 5 mcg |
Inactive ingredients: 30% propylene glycol, citric acid and/or sodium citrate for pH adjustment, and water for injection.
INFUVITE ADULT makes available a combination of important oil-soluble and water-soluble vitamins in an aqueous solution, formulated for incorporation into intravenous solutions. The liposoluble vitamins A, D, E, and K have been solubilized in an aqueous medium with polysorbate 80, permitting intravenous administration of these vitamins.
Contains no more than 70 mcg/L of aluminum (combined Vials 1 and 2).
INFUVITE ADULT is a combination of vitamins indicated for the prevention of vitamin deficiency in adults and children aged 11 and older receiving parenteral nutrition.
The physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy.
INFUVITE ADULT is a combination product that contains the following vitamins: ascorbic acid, vitamin A, vitamin D, thiamine, riboflavin, pyridoxine, niacinamide, dexpanthenol, vitamin E, vitamin K1, folic acid, biotin, and vitamin B12
INFUVITE ADULT is supplied as a single dose or as a pharmacy bulk package for intravenous use intended for administration by intravenous infusion after dilution.
Patients with multiple vitamin deficiencies or with increased vitamin requirements may need multiple daily dosages as indicated. Some patients do not maintain adequate levels of certain vitamins when this formulation in recommended amounts is the only source of vitamins.
Do not administer INFUVITE ADULT as a direct, undiluted intravenous injection as it may cause dizziness, faintness, and possible tissue irritation.
Blood vitamin concentrations should be monitored to ensure maintenance of adequate levels, particularly in patients receiving parenteral multivitamins as the only source of vitamins for long periods of time.
is an injection for intravenous administration consisting of two vials labeled Vial 1 (5 mL) and Vial 2 (5 mL). For the vitamin strengths [see DESCRIPTION].
is an injection for intravenous administration consisting of two vials labeled Vial 1 (50 mL) and Vial 2 (50 mL Fill in 100 mL Vial). The mixed solution (100 mL) will provide ten 10 mL single doses. For the vitamin strengths [see DESCRIPTION].
Vial 1 (Single Dose and Pharmacy Bulk Package) is supplied as clear, yellow to orange liquid in amber glass vial closed with a rubber stopper, clear aluminum seal and a white flip-off.
Vial 2 (Single Dose and Pharmacy Bulk Package) is supplied as clear, colorless to pale yellow liquid in amber glass vial closed with a rubber stopper, clear aluminum seal and a deep purple flip-off.
INFUVITE ADULT (multiple vitamins injection) is supplied as follows:
Vial 1 (Single Dose and Pharmacy Bulk Package) is supplied as clear, yellow to orange liquid in amber glass vial closed with a rubber stopper, clear aluminum seal and a white flip-off.
Vial 2 (Single Dose and Pharmacy Bulk Package) is supplied as clear, colorless to pale yellow liquid in amber glass vial closed with a rubber stopper, clear aluminum seal and a deep purple flip-off.
INFUVITE ADULT Single Dose:
| Carton contains total ten single-dose vials | NDC 54643-5649-1 |
| Five of Vial 1 (5 mL) | NDC 54643-5657-1 |
| Five of Vial 2 (5 mL) | NDC 54643-5659-1 |
One Vial 1 plus one Vial 2 to be used for a single dose [see DOSAGE AND ADMINISTRATION].
INFUVITE ADULT Pharmacy Bulk Package:
| Carton contains total two vials | NDC 54643-5650-2 |
| One Vial 1 (50 mL) | NDC 54643-5661-2 |
| One Vial 2 (50 mL Fill in 100 mL Vial) | NDC 54643-5663-2 |
Mix contents of Vial 1 with Vial 2 to provide 10 single doses [see DOSAGE AND ADMINISTRATION].
Minimize exposure of INFUVITE ADULT to light because vitamins A, D and riboflavin are light sensitive.
Store under refrigeration, 2°C to 8° C (36°F to 46° F).
Manufactured for: Sandoz Inc., Princeton, NJ 08540. Revised: Nov 2024
The following adverse reactions are discussed in greater detail in other section of the labeling.
The following adverse reactions have been identified during postapproval use of INFUVITE ADULT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Dermatologic: rash, erythema, pruritis
CNS: headache, dizziness, agitation, anxiety
Ophthalmic: diplopia
A number of interactions between vitamins and drugs have been reported. The following are examples of these types of interactions:
Vitamin K, a component of INFUVITE ADULT, antagonizes the anticoagulant action of warfarin. In patients who are co-administered warfarin and INFUVITE ADULT, blood levels of prothrombin/INR should be monitored to determine if dose of warfarin needs to be adjusted [see WARNINGS AND PRECAUTIONS].
Thiamine, riboflavin, pyridoxine, niacinamide, and ascorbic acid decrease antibiotic activities of erythromycin, kanamycin, streptomycin, doxycycline, and lincomycin.
Ascorbic acid and riboflavin inactivate bleomycin in vitro, thus the activity of bleomycin may be reduced.
Pyridoxine may increase the metabolism of levodopa (decrease blood levels of levodopa) and decrease its efficacy.
Folic acid may increase phenytoin metabolism and lower the serum concentration of phenytoin resulting in increased seizure activity.
Folic acid may decrease a patient’s response to methotrexate therapy.
Concomitant administration of hydralazine or isoniazid may increase pyridoxine requirements.
Phenytoin may decrease serum folic acid concentrations.
In patients with pernicious anemia, the hematologic response to vitamin B12 therapy may be inhibited by chloramphenicol.
Included as part of the "PRECAUTIONS" Section
INFUVITE ADULT contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solution, which contain aluminum.
Research indicates that patients with impaired kidney function, including premature neonates who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration. To prevent aluminum toxicity periodically monitor aluminum levels with prolonged parenteral administration of INFUVITE ADULT in patients with renal impairment.
Allergic reactions such as urticaria, shortness of breath, wheezing and angioedema have been reported following intravenous administration of thiamine, which is found in INFUVITE ADULT. There have been rare reports of anaphylactoid reactions following intravenous doses of thiamine. No fatal anaphylactoid reactions associated with INFUVITE ADULT have been reported.
Hypervitaminosis A, manifested by nausea, vomiting, headache, dizziness, blurred vision has been reported in patients with renal failure receiving 1.5 mg/day retinol and in patients with liver disease, Therefore, supplementation of renal failure patients and patients with liver disease with vitamin A, an ingredient found in INFUVITE ADULT, should be undertaken with caution [see Use In Specific Populations].
INFUVITE ADULT contains Vitamin K, which may decrease the anticoagulant action of warfarin. In patients who are on warfarin anticoagulant therapy receiving INFUVITE ADULT monitor blood levels of prothrombin/INR to determine if dose of warfarin needs to be adjusted.
INFUVITE ADULT contains folic acid and cyanocobalamin which can mask serum deficiencies of folic acid and cyanocobalamin in patients with megaloblastic anemia. Avoid the use of INFUVITE ADULT in patients with suspected or diagnosed megaloblastic anemia prior to blood sampling for the detection of the folic acid and cyanocobalamin deficiencies.
In patients receiving parenteral multivitamins such as with INFUVITE ADULT, blood concentration should be periodically monitored to determine if deficiencies or excesses are developing. INFUVITE ADULT may not correct longstanding specific vitamin deficiencies. The administration of additional therapeutic doses of specific vitamins may be required [see DOSAGE AND ADMINISTRATION ].
INFUVITE ADULT contains vitamin C which is also known as ascorbic acid. Ascorbic acid in the urine may cause false negative urine glucose results.
Carcinogenicity, mutagenicity, and fertility studies have not been performed with INFUVITE ADULT.
Administration of the approved recommended dose of INFUVITE ADULT in parental nutrition is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. Pregnant patients should follow the U.S. Recommended Daily Allowances for pregnancy because their vitamin requirements may exceed those of nonpregnant patients. Deficiency of essential vitamins may result in adverse pregnancy outcomes (see Clinical Considerations). Animal reproduction studies have not been conducted with INFUVITE ADULT.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15- 20%, respectively.
Disease-associated Maternal and/or Embryo-Fetal Risk
Deficiency of essential vitamins has been associated with adverse pregnancy and fetal outcomes, such as maternal folic acid deficiency and an increased risk of neural tube defects. Therefore, parenteral nutrition with multiple vitamins injection should be considered if a pregnant woman’s nutritional requirements cannot be fulfilled by oral or enteral intake.
Multiple vitamins present in INFUVITE ADULT are also present in human milk. Administration of the approved recommended dose of INFUVITE ADULT In parental nutrition is not expected to cause harm to a breastfed infant. There is no information on the effects of INFUVITE ADULT on milk production. Lactating patients should follow the U.S. Recommended Daily Allowances for their condition, because their vitamin requirements may exceed those of nonlactating patients. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for INFUVITE ADULT and any potential adverse effects on the breastfed child from INFUVITE ADULT or from the underlying maternal condition.
Safety and effectiveness in children below the age of 11 years have not been established.
Safety and effectiveness for geriatric use have not been established.
INFUVITE ADULT has not been studied in patients with renal impairment. Monitor renal function, calcium, phosphorus and vitamin A levels in patients with renal impairment [see WARNINGS AND PRECAUTIONS].
INFUVITE ADULT has not been studied in patients with liver impairments. Monitor vitamin A level in patients with liver disease, high alcohol consumption [see WARNINGS AND PRECAUTIONS ].
Signs and symptoms of acute or chronic overdosage may be those of individual INFUVITE ADULT component toxicity.
In post-marketed surveillance, overdosage with INFUVITE ADULT at two times the prescribed dose did not result in toxicity.
INFUVITE ADULT is contraindicated in patients who have
No Information Provided
No Information Provided
Instruct patients (if age appropriate) and caregivers:
